A special video supplement to a CME conference held during the
61st ASH Annual Meeting featuring expert comments on the
management of acute myeloid leukemia. Featuring perspectives from
Dr Richard M Stone.
Design and results of the QUAZAR AML-001 maintenance trial
assessing CC-486 versus placebo for patients with AML in first
remission (00:00)
Mechanism of action of azacitidine in AML (04:09)
Preclinical data on the use of anti-inflammatory agents for
clonal hematopoiesis of indeterminate potential (CHIP) (05:56)
Ongoing investigations of anti-CD47 antibodies, antibody-drug
conjugates and immune checkpoint inhibitors for AML (07:40)
Clinical relevance of CHIP mutations (11:05)
Pathophysiology of CHIP mutations and cardiovascular disease
(16:23)
Composition of CPX-351; advantages and disadvantages in the
management of AML (17:45)
Efficacy and safety of CPX-351 for secondary AML; patient
selection for treatment with CPX-351 (20:10)
Investigation of venetoclax-based combination strategies in AML
(23:27)
Factors determining eligibility for intensive chemotherapy for
older and younger patients with AML (26:10)
Counseling patients on potential outcomes of intensive
chemotherapy for AML (30:51)
Duration of therapy with an HMA and venetoclax for patients
with AML (34:27)
Genetic alterations in AML; incidence and biology of FLT3
mutations (36:12)
Clinical presentation of patients with AML with FLT3 mutations;
activity of the FLT3 inhibitors gilteritinib and midostaurin
(38:44)
Role of FLT3 inhibitors as a bridge to transplant and in the
post-transplant setting (42:12)
Tolerability of FLT3 inhibitors for patients with AML and
choice of agent in the post-transplant maintenance setting
(45:18)
Evidence with and ongoing investigation of the FLT3 inhibitor
quizartinib in patients with AML with a FLT3 mutation (47:28)
Incidence of IDH mutations in AML; treatment for AML with IDH1
and IDH2 mutations (49:45)
Differentiation syndrome with IDH inhibitors: Incidence,
presentation and management (54:20)
Treatment options for patients with AML harboring IDH or FLT3
mutations who are unfit for intensive chemotherapy (57:02)
Future developments in the management of AML (59:28)
Long-term outcomes with HMA and venetoclax in AML
(1:01:32)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.